Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia

Belch, Jill; Hiatt, William R; Baumgartner, Iris; Driver, I Vickie; Nikol, Sigrid; Norgren, Lars; Van Belle, Eric; TAMARIS Committees, ; Investigators, (2011). Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet, 377(9781), pp. 1929-37. London: Elsevier 10.1016/S0140-6736(11)60394-2

Full text not available from this repository. (Request a copy)

Patients with critical limb ischaemia have a high rate of amputation and mortality. We tested the hypothesis that non-viral 1 fibroblast growth factor (NV1FGF) would improve amputation-free survival.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Baumgartner, Iris

ISSN:

0140-6736

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:11

Last Modified:

04 May 2014 23:05

Publisher DOI:

10.1016/S0140-6736(11)60394-2

PubMed ID:

21621834

Web of Science ID:

000291623200029

URI:

https://boris.unibe.ch/id/eprint/2216 (FactScience: 204514)

Actions (login required)

Edit item Edit item
Provide Feedback